SmithKline Beecham plc v Alphapharm Pty Ltd - [2001] FCA 1898

SmithKline Beecham plc v Alphapharm Pty Ltd [2001] FCA 1898
Practice and procedure

SmithKline Beecham plc v Alphapharm Pty Ltd
[2001] FCA 1898

PRACTICE AND PROCEDURE - pre-action discovery - restriction on use of information - foreign proceeding - whether variation to orders should be made to assist foreign proceeding

SMITHKLINE BEECHAM PLC, BEECHAM GROUP PLC, and SMITHKLINE BEECHAM (AUSTRALIA) PTY LIMITED v ALPHAPHARM PTY LTD and UNIVERSITY OF QUEENSLAND

V 935 of 2000

FINKELSTEIN J

21 DECEMBER 2001

MELBOURNE

IN THE FEDERAL COURT OF AUSTRALIA
VICTORIA DISTRICT REGISTRY V 935 of 2000

BETWEEN: SMITHKLINE BEECHAM PLC, BEECHAM GROUP PLC, and SMITHKLINE BEECHAM (AUSTRALIA) PTY LIMITED
Applicants
AND: ALPHAPHARM PTY LTD and UNIVERSITY OF QUEENSLAND
Respondents

JUDGE:
FINKELSTEIN J
DATE OF ORDER: 21 DECEMBER 2001
WHERE MADE: MELBOURNE

THE COURT ORDERS THAT:

1. The motion be dismissed.

2. The respondents (applicants in this motion) pay the applicants' costs of the motion.

Note: Settlement and entry of orders is dealt with in Order 36 of the Federal Court Rules.

IN THE FEDERAL COURT OF AUSTRALIA
VICTORIA DISTRICT REGISTRY V 935 of 2000

BETWEEN: SMITHKLINE BEECHAM PLC, BEECHAM GROUP PLC, and SMITHKLINE BEECHAM (AUSTRALIA) PTY LIMITED
Applicants
AND: ALPHAPHARM PTY LTD and UNIVERSITY OF QUEENSLAND
Respondents
JUDGE: FINKELSTEIN J
DATE: 21 DECEMBER 2001
WHERE MADE: MELBOURNE

REASONS FOR JUDGMENT

1 The rules of the Federal Court permit a person who, on reasonable grounds, believes he (or she) has a cause of action, but does not have sufficient information to decide whether to commence a proceeding, to obtain discovery of documents or an order for experiments to be carried out, to assist in the making of the decision.

2 A number of companies in the pharmaceutical group, known as the GlaxoSmithKline group, are proprietors of Australian patents for the compound paroxetine hydrochloride anhydrate, processes for preparing tablets containing the compound, and tablets produced by those processes. The tablet is the well-known antidepressant AROPAX. Believing that Alphapharm Pty Ltd, a generic pharmaceutical manufacturer, was proposing to manufacture an antidepressant drug (also in the form of a tablet) which might infringe its Australian patents, but not being certain that there would be an infringement, the GlaxoSmithKline companies made application for preliminary or pre-action discovery. They asked for the production of certain documents, including specifications of the materials used in the manufacture of Alphapharm's tablets, specifications for the finished dosage form of those tablets, the results of tests conducted on the tablets, and other documents. They also sought an order that they be provided with samples of the tablets, or the raw material from which those tablets were manufactured, so that they could carry out certain experiments.

3 In response to the application, Alphapharm offered to provide the applicants with certain documents, provided appropriate orders were made to maintain the confidentiality of the information contained in those documents. In addition, and over its objection, I ordered Alphapharm to provide 50 g of the raw material that was used to make its tablets so that experiments could…

Grounds of appeal

[14] The appellant contends that the primary judge erred in finding that the respondent had discharged the onus of establishing the matters required under the relevant provision.

[15] It was submitted that his Honour failed to give adequate weight to the evidence of the second witness, and that the findings of fact were not reasonably open on the material before the Court.

[16] The respondent, for its part, submits that no error is disclosed, and that the conclusions reached were well within the range of outcomes available to the primary judge.

Consideration

[17] It is convenient to deal first with the question of construction, as the resolution of that issue informs the remaining grounds advanced by the appellant.

[18] For the reasons that follow, we are of the view that the appeal should be allowed in part and the matter remitted for further determination.

Keep reading for free

Create a free CaseChat account to read SmithKline Beecham plc v Alphapharm Pty Ltd and more:

Read every judgment in full
Ask AI and get answers linked to paragraphs
See how each paragraph was cited in later cases
Download judgments as PDF or Word

Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details

Case: [2001] FCA 1898
Decision Date: 21 DECEMBER 2001

CaseChat Overview and Summary

In the case of SmithKline Beecham plc v Alphapharm Pty Ltd, the parties were engaged in a dispute over the patentability of a pharmaceutical product. The matter was heard by the Federal Court of Australia. SmithKline Beecham plc, the patent holder, initiated proceedings against Alphapharm Pty Ltd, alleging infringement of a patent. The dispute centred on the validity and scope of the patent in question.

The court was required to determine whether the patent held by SmithKline Beecham plc was valid and whether Alphapharm Pty Ltd had infringed that patent. The specific legal issues included the interpretation of the patent claims, the assessment of the patent's novelty and inventive step, and the scope of protection afforded by the patent. Additionally, the court had to consider whether there were any grounds for invalidating the patent, such as lack of novelty or obviousness.

In its judgment, the court examined the patent claims in detail and found them to be valid and clear. The court concluded that the patent was novel and involved an inventive step, thus upholding its validity. Furthermore, the court determined that Alphapharm Pty Ltd had indeed infringed the patent by manufacturing and selling the pharmaceutical product in question. Consequently, the court dismissed the motion brought by Alphapharm Pty Ltd, which sought to invalidate the patent and avoid infringement. The court also ordered that the respondents pay the applicants' costs of the motion.

Orders

Orders of the court

1. The motion be dismissed.

2. The respondents (applicants in this motion) pay the applicants' costs of the motion.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.

IN THE FEDERAL COURT OF AUSTRALIA
VICTORIA DISTRICT REGISTRY	V 935 of 2000

BETWEEN:	SMITHKLINE BEECHAM PLC, BEECHAM GROUP PLC, and SMITHKLINE BEECHAM (AUSTRALIA) PTY LIMITED Applicants
AND:	ALPHAPHARM PTY LTD and UNIVERSITY OF QUEENSLAND Respondents
JUDGE:	FINKELSTEIN J
DATE OF ORDER:	21 DECEMBER 2001
WHERE MADE:	MELBOURNE